Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

May 13, 2023

Study Completion Date

May 13, 2023

Conditions

Acute-graft-versus-host DiseaseChronic Graft-versus-host-diseaseSolid Organ Transplant

Interventions

DRUG

Ruxolitinib

Ruxolitinib will be given by mouth or enteral tube (if applicable).

Trial Locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT05121142 - Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter